Abstract: Seventy years ago it was discovered that glutamate plays a central role in brain metabolism and is abundant in the brain. Glutamate was then found to be the principal excitatory neurotransmitter in the brain. As stated in the first article of this series, there are three families of ionotropic receptors with intrinsic cation permeable channels: Nmethyl-D-aspartate [NMDA], α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA] and kainate [Ka].
Introduction and Overview
It is now recognized that three major categories of s u b s t a n c e s a c t a s n e u r o t r a n s m i t t e r s .
T h e s e neurotransmitters include amino acids ( 1 . Glu is the most common of these neurotransmitters, as L-glutamic acid is present in most foods, found in either the free form or bound to peptides and proteins 2 . In fact, the Glu system is ubiquitous across most animal taxa 3 -Glu receptor genes have been found in plants 4 .
The glutamatergic synaptic transmission in the mammalian central nervous system [CNS] has been investigated since the 1950s 1, 5, 6 . Realization that Glu and similar excitatory amino acids [EAA] , such as domoic acid [DMA] , mediated their excitatory actions via multiple receptors preceded establishment of these receptors as synaptic transmitter receptors, in contrast to GABA and Gly which are major inhibitory neurotransmitters 3, 7 .
The most abundant molecular component of the Glu system is N-acetyl aspartylglutamate [NAAG] 8 . It has been calculated that a 70-kg man has a daily Glu intake of ~ 28 g, and a daily Glu turnover of ~ 48 g, of this compound derived from the diet and from the breakdown of gut proteins. Despite this large turnover, the total pool of glutamic acid in blood is quite small, ~ 20 mg, because of its rapid extraction from and utilization by various tissues, particularly muscle and liver 7, 9 . The human body contains about 10 grams of free Glu; brain 2.3 g, muscle 6 g, liver 0.7 g, kidneys 0.7 g, and blood 0.04 g 10 . Glutamate receptors [GluR] perform a variety of functions in the CNS and peripheral nervous systems [PNS] such as learning, memory 11 , anxiety, the perception of pain as well as immune function 12 . They consist of two subtypes: ionotropic [iGlu] and metabotropic [mGlu] .
Ionotropic glutamate receptors [iGluRs] , sometimes referred to as ligand-gated ion channels [LGIC] , are a group of transmembrane ion channels that open in response to a chemical messenger, e.g., N-methyl-D-aspartic acid
[NMDA], Kainate [Ka] and α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid [AMPA] . These LGICs are different than voltage-gated ion channels or stretch-activated ion channels.
Metabotropic glutamate receptors [mGluRs] are active through an indirect metabotropic process. They are members of the Group C family of G-protein-coupled receptors 1 3 -1 5 . Molecular cloning techniques have elucidated eight mGluR subtypes to date 16 , some of which include alternately spliced variants 13, 14 . The mGluRs have been divided into three groups based on sequence homology: Group I includes mGluR 1 16 , and for the NMDA iGluR 18 . mGluRs are found 19 in pre-and postsynaptic neurons in synapses of the hippocampus, cerebellum 20 , cerebral cortex 21 , as well as other parts of the brain and in peripheral tissues 22, 23 . Like other metabotropic receptors, mGluRs have seven transmembrane domains that span the cell membrane 23 . Unlike ionotropic receptors, metabotropic receptors are not directly linked to ion channels, but may affect them by activating biochemical cascades. They can release Ca ++ from intracellular structures where it is stored, such as the endoplasmic reticulum [ER] . Here, activation of mGluRs causes the production of inositol triphosphate, which in turn activates receptors on the ER that open Ca ++ -permeable channels. In addition to producing excitatory and inhibitory postsynaptic potentials, mGluRs serve to modulate the function of other receptors, such as NMDA receptors, by changing the synapse's excitability 15, 16, 23, 24 . Endogenous Glu, by activating NMDA, AMPA or mGluR 1 receptors, may contribute to the brain damage occurring acutely after status epilepticus, cerebral ischemia or traumatic brain injury 25 . Endogenous Glu may also contribute to chronic neurodegeneration in such disorders as amyotrophic lateral sclerosis [ALS] 26 , Alzheimer's disease [AD] 27 , Parkinson's disease [PD] 28 , Multiple sclerosis [MS] 29 , and Huntington's disease [HD] 30 . For example, in animal models NMDA and AMPA receptor antagonists protect against acute brain damage and delayed behavioral deficits 31, 32 . It is the purpose of this second part of this review (Part II) to relate changes in these receptors to the pathology and pathophysiology of a number of diseases. In the first part of this review (Part I), the biological activities of the Glu system were summarized and discussed. An effort has been made to address the toxicologic pathology of these receptors in a number of diseases, particularly diseases of the CNS, whenever data are available.
Pathophysiology and Pathology related to Glutamate
As mentioned in the introduction, there is adequate direct and circumstantial evidence for abnormal Glu and Glu analogue transmission in the etiology and pathophysiology of many neurological and psychiatric disorders 13, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . The mechanism by which Glu is involved in the pathogenesis of these disease is probably through its excitotoxic effects 49 , which can be pronounced during acute events such as ischemic stroke and trauma, or milder but prolonged in chronic neurodegenerative diseases such as AD, PD, HD and ALS [50] [51] [52] [53] . In addition there appears to be a role for Glu, Gly, and GABA and their regulation in manganese [ . Glu also has been implicated in long-term plastic changes in the CNS [55] [56] [57] [58] [59] , such as learning 60 chronic pain, drug tolerance, dependence, addiction, partial complex seizures and tardive dyskinesia 36, 46, 61, 62 . As more knowledge regarding the specifics of all GluRs and their interactions, targeted drug development may be possible for those diseases where Glu plays a central role in its pathogenesis 63 . The CNS is not alone in its response to Glu-related effects. Many tissues demonstrate Glu, GluRs, and glutamate transporters [GluT] activity, in addition to the CNS 22 . In fact, any tissue that has any central CNS, peripheral [PNS] or autonomic nervous system [ANS] components usually show Glu-related activity; however, these are not the only cell types to show such activity, e.g., skeletal muscle .
Glutamate or related EAAs in pathological processes
Glu or related EAAs can cause neuronal injury as a result of over excitation by excitotoxicity via exogenous and endogenous exposure 1 1 3 , probably via the NMDA receptor 114 . It is now known that GluRs are important in fetal development 115 and act as mediators of inflammation and cellular injury through apoptosis and necrosis 32, [41] [42] [43] 116, 117 , and as such have been suggested that EAA research may lead to a better understanding of the pathogenesis of these disease entities 118 . GluRs have been reported to be associated with apoptosis and necrosis 119 , the former demonstrating no inflammation in conjunction with the cellular degeneration and the later is characterized by an inflammatory reaction, edema, and injury to the surrounding tissue following the release of intracellular constituents that evoke a local inflammatory response 120 . The determinant as to whether apoptosis or necrosis will occur under Glu stress is the degree of damage to the mitochondria, where minor damage results in apoptosis and severe damages produces necrosis 119 . Regardless of the mechanism of cell death, Ca ++ influx is central to neurodegeneration 121 . Inflammation, a hallmark of necrosis, causes marked alterations in regional cell membrane transport and intracellular glutamine 122 . Here, the increased endogenous glutamine biosynthesis cannot keep up with the new demand resulting a deletion of the glutamine pool, as the liver and other viscera increase their uptake of glutamine during inflammation 122 . As Glu ameliorates endotoxic shock and asthma through the inhibition of cytosolic phospholipase A(2) (cPLA(2)) activity, it is possible that reduced available Glu may increase the inflammatory response. Because of these observations, clinical treatment with Glu has been suggested 123 . As inflammation is often part of the neoplastic process and the glutamatergic system has been implicated in tumour biology 124, 125 , investigation of the glutamatergic system with respect to cancer biology has been explored to some extent 126 . In fact, paraneoplastic ataxia in patients with gynecologic cancer, breast cancer, lung cancer, or Hodgkin's disease has been associated with autoantibodies against GluRs aberrantly expressed by the tumor cells 1 2 7 . Paraneoplastic effects are numerous and include neurological, muscular, dermal, renal and bone marrow detrimental effects.
Not all effects on Glu, GluRs and GluTs are endogenous, or exogenously obtained via the diet. A number of reptilian and arachnid venoms have be show to affect their toxicity via inhibition of the activity of GluRs. For example, Araneus gemma, Neoscona arabesca, and Argiope aurantia all have shown inhibitory effects on the synaptic Glu releasing membrane 128 .
Neurons
Apoptosis and necrosis in neurons often occurs due to osmotic damage due to the influx of Ca ++ and water particularly in mitochondria 129 . Because the iGluRs are iongated channels selective to sodium [ . The intracellular increase in Ca ++ concentration in neurons activates phospholipases, protein kinase C, proteases, protein phosphatases, nitric acid synthases 131 and the generation of free radicals 32, 35, 37, 38, 41, 43, 49, [76] [77] [78] 88, 91, [132] [133] [134] [135] [136] . Activation of phospholipase A2 results in the generation of arachidonic acid, its metabolites and platelet-activating factors [PAF] . PAF increase the neuronal Ca ++ levels by stimulating the release of Glu and corresponding increased influx of ions through iGlu ion-gated channels 137 . Not only the release of Glu is increased by this stimulation, but also arachidonic acid potentiates NMDA evoked currents and inhibits the reabsorption of Glu into astrocytes and neurons. These events further exacerbate the situation by a positive feedback mechanism where free radicals are formed during arachidonic acid metabolism, leading to further phospholipase A2 activation. The result is an increased concentration of extracellular Glu, which contribute to the sustained activation of the GluRs 37,38,49,138 . As a consequence of this sustained activation, cysteine transport is inhibited causing a decrease of intracellular reducing sulphydryl groups and the generation of oxygen free radicals, which results in death of neurons through lack of cation control and influx of Ca ++ 117 . In addition to enzymes of the cell cytosol, free radicals contribute to the DNA fragmentation, and the activation of nuclear enzymes such as endonucleases are also activated by increase of Ca ++ resulting in apoptosis. On the other hand, if severe damage results in rupture of lysozomes and extracellular release of intact and enzymatically modified cellular organelles, necrosis and subsequent inflammation will occur 120, 139 . Nitric oxide [NO] has also been shown to be a neurotransmitter in the parasympathetic postganglionic neurons and in preganglionic sympathetic neurons 140 . The increased concentration of neuronal intracellular Ca ++ also raises the NO concentration via the calmodulin activation of nitric oxide synthetases [NOS] . An increase in NO generates more oxygen free radicals that further damage the integrity of the cell membrane 140 . Because the NO is Ca ++ -and calmodulin-dependent and the AMPA receptors are Ca ++ permeable, it is possible that NO is activated through AMPA receptors.
Neurons are not the only cell type in the nervous system to be damaged by high concentrations of Glu, probably in conjunction with NO 141 . Oligodendrocytes play an important role in axonal conduction in the CNS and are sensitive to oxidative toxicity induced by Glu in the absence of iGluR. The sensitivity to Glu in the absence of GluR might indicate that olidendroglia are more sensitive to Glu damage than neurons.
Oligodendrocytes
Functional p r e s s i o n v i a N O S -2 i n p r i m a r y c u l t u r e s o f oligodendrocytes stimulated by cytokines. The present view is that immature oligodendrocytes express NOS-2, but that they do not when they are mature, which raises questions about the regulation of NOS-2 expression in microglia that may become oligodendrocytes. Recently, it has been suggested that that constitutive nitric oxide synthase type II [NOS-3] expression may play a key role in oligodendrocytic injury due to its activation by Ca ++ , in interaction with pathways mediating Glu toxicity 151 .
Astrocytes
Astrocytes also have been shown to play an important role to play in Glu neurotoxicity 152 . A co-culture system combining cerebellar cells and astrocytes has been used to investigate the astrocytic control of Glu toxicity 153 . The coculture of astrocytes with cerebellar neurons enhances uptake of Glu by astrocytes, but inhibition of Glu uptake in this system leads to death of neurons, indicating the necessity of Glu for normal neural functioning. However, in the presence of the Glu uptake inhibitor, no observed increase of Glu in the cultures, compared with those that were not co-cultured, indicates an interaction of astrocytes and neurons in Glu toxicity.
These findings indicate that neurons become more susceptible to Glu toxicity in the presence of astrocytes and thus become dependent on astrocytes for prevention of Glu toxicity. Astrocytes treated with conditioned medium from cerebellar cells did not show an increase in Glu uptake but astrocytes exposed to neuron conditioned medium were toxic to cerebellar cells, due to Glu present in the medium. In fact, concentrations of Glu required to produce neurotoxicity in the absence of astrocytes was 100 times that required to produce neurotoxicity in the presence of abundant astrocytes 154 . These observations suggest that a soluble factor released by neurons, signals to astrocytes that neurons are present and stimulates a signal back to neurons, which causes an increased sensitivity to Glu toxicity 1 5 3 . Alternatively, GluTs could be involved, where a malfunction in GluTs may lead to an excessively high extracellular Glu concentration resulting in neurodegeneration caused by Glu excitotoxic effects 155 .
Central nervous system disorders
Neurons that contain Glu, also contain GluRs and make up an extensive network throughout the cortex, hippocampus, striatum, thalamus, hypothalamus, cerebellum, and visual and auditory system in the CNS 43,156-159 can be found in both grey and white matter 159 . As a consequence, Glu neurotransmission has been recognized as essential for cognition, memory, movement and sensation; especially taste, sight, and hearing 43 . In addition, Glu has been shown to cause a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor 160, 161 . A broad range of chronic neurodegenerative diseases listed above are now believed to be caused, at least in part, b y t h e e x c i t o t o x i c a c t i o n o f G l u a n d a s p a r t a t e [Asp] 43,156,157,162-164 . It is possible that Glu and Asp excitotoxity causes memory loss, confusion, and mild intellectual deterioration that frequently occur in late middle age to old age 32 . Glu clearly plays an important role in neuronal differentiation, migration and survival in the developing brain. Its activity is largely through facilitating the entry of Ca ++ 165,166 . Blockade of NMDA receptors during the prenatal period with compounds such as phencyclidine [PCP] or ethanol [167] [168] [169] [170] , can induce apoptosis in vulnerable neurons, the selectivity of which depends on the developmental stage 171 . Such degeneration is probably responsible in part for the neurological development syndromes including fetal alcohol syndrome.
Exogenous glutamate and neurodegeneration
Glu has three distinct possible mechanisms of action in acute or chronic neurodegenerative processes resulting from agonist effect on NMDA, AMPA, and Ka or Group I metabotropic receptors 32 . These mechanisms include exogenous Glu, or related compounds acting on GluRs, can be consumed in the diet and damage the brain; endogenous Glu released from neurons can contribute to acute neurodegeneration occurring in relation to cerebral ischemia or traumatic brain injury; and activation of Glu receptors contributes to the process of cell death in chronic neurodegenerative disorders 32 . In the case of exogenous Glu and other analogues poisoning, the first process is mainly in effect.
Monosodium glutamate: There is general controversy regarding toxicity of monosodium glutamate [MSG] . In the late 1960s numerous case reports appeared in the scientific literature describing a complex of symptoms which came to be known as the Chinese restaurant syndrome [CRS] because they typically followed ingestion of a Chinese meal 90 . The most frequently reported symptoms include headache, numbness, tingling, flushing, muscle tightness, and generalized weakness. Investigations have mainly focused on MSG as the causative agent.
More recently, the term MSG symptom complex has been used instead of CRS. The prevalence of CRS is not really known but is suggested that it affects between one and two percent of the general population. The reports of MSGtriggered CRS were followed in the early 1980s by reports of a possible association between MSG and the triggering of bronchospasm and bronchoconstriction in small numbers of asthmatics. While a number of mechanisms have been proposed to explain how MSG might trigger the various reported reactions, none has been proven, and very little follow-up research has been conducted to investigate further any of the proposed mechanisms 172 . There is no convincing evidence that MSG is a significant factor in causing systemic reactions resulting in severe illness or mortality 173, 174 . Studies conducted to date on CRS have largely failed to demonstrate a causal association with MSG. Symptoms resembling those of CRS may be provoked in a clinical setting in small numbers of individuals by the administration of large doses of MSG without food [175] [176] [177] . However, such affects are neither persistent nor serious and are likely to be attenuated when MSG is consumed with food 178 . In terms of more serious adverse effects such as the triggering of bronchospasm in asthmatic individuals, the evidence does not indicate that MSG is a significant trigger factor 172 . However, due to the individual nature of hypersensitivity, it would not be wise to rule out the possibility that some susceptible individuals are affected even though reviews suggest that there is no consistent evidence to suggest that individuals may be uniquely sensitive to MSG 179 . Contrasting these findings that point to are the definite effects of MSG on organ systems in experimental models. In the CNS, MSG has been shown to cause neuronal cell death 180 , a deficit in hippocampal long term potentiation [LTP] in rats 181 , learning disabilities 182 , behavioral deficits in adult rats 183 , delayed coordination of neonates 184 , retinal damage 185 , hepatic, and renal toxicity 186 . It should be noted that very large doses of MSG, which could be considered toxic, were used in these experiments. As we have seen that Glu has a double action-neurotransmitter at low doses and neurotoxicant at high doses-extrapolation of these results to the real life situation should be done with extreme caution.
Domoic acid: The classical CNS effects of poisoning with an exogenous Glu analog domoic acid [DMA] , an agonist of non-NMDA receptor subtype including Ka receptor 187, 188 , has allowed detailed neuropathological evaluation of animal and human tissues 94, 132, 187, 189 . As with other excitotoxins, DMA causes neurotoxicity via Ca ++ influx into neurons 190 . In neuropathological studies in four elderly men who succumbed to the toxin after days revealed extensive bilateral limbic system pathology with neuronal loss in cellular zones of hippocampus (CA 1 , CA 3 , dentate gyrus), amygdala, claustrum, septal area, thalamus and insular and sub frontal cortex 32 . The altered morphology seen following DMA toxicity is a consequence seizure activity, involving mainly the limbic system, rather than the effect of a direct excitotoxic action of domoate, as almost all of the pathology, except for CA 3 cell loss and sometimes some amygdala damage, is prevented by the administration of an Ka/AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione [NBQX] 191 . It is likely that only the CA 3 neurons die as a direct result of the excitotoxic action of domoate, hence the retrograde amnesia often noted in those poisoned with DMA. The morphology following direct injection of DMA into the hippocampus has been characterized by severe neuronal necrosis 192 , although this experiment did not model the natural exposure route and dose.
Neurolathyrism: β-N-Oxalylamino-L-alanine [BOAA] , also referred to as β-N-oxalyl-α,β-diaminopropionic acid [β-ODAP], is a toxin found in chick peas thought to be responsible for the syndrome of neurolathyrism. Neurolathyrism, which causes a motor disability as a result of loss of upper motor neurons is seen predominantly in malnourished young men and can have an acute or semi acute onset 193 . BOAA is a selective agonist for AMPA receptors and can cause excitotoxic cell death in neonatal rodents or in tissue culture 194 . However, BOAA does not produce the specific pathology of neurolathyrism in rodents or primates, although a transient neurological syndrome has been described in monkeys 32 . It is possible that the human syndrome depends on some vitamin or other deficiency that impairs mitochondrial metabolism and renders neurons unusually vulnerable to an AMPA agonist. , present in the fruit of the cycad plant that grows in Guam, has been proposed as the dietary toxin responsible for ALSG 195 . BMAA is not directly excitotoxic, but becomes toxic in the presence of bicarbonate 196 . In rats, acute excitotoxicity is seen in the cerebellum after administration of very high doses (1-4 g/ kg) of BMAA, probably mediated through the excitotoxic effects of Glu, GluRs, and GluTs; however, the low level of consumption and the very long latent period make it extremely unlikely that BMAA is acting as an excitotoxin to produce ALSG. The question of how cycad toxicity and ALSG relate, and the mechanisms by which such lesions occur is unclear and is still being explored 195, 196 . Mitochondrial toxins and excitotoxic lesions in the striatum: Another mechanism whereby activation of GluRs leads to neurodegeneration involves mitochondrial toxins, such as malonate and 3-nitropropionic acid [3- 201 . There is a complex interaction between the ionic changes, altered energy metabolism, the poisoning of mitochondria and oxidative or free radical-mediated damage 202 , leading to neuronal death. Probably the simplest outcome of these interactions is the production of Ca-lipid "soaps", which prevent oxidative phosphorylation.
Selective antagonists can be used to show the role of the LGICs; thus, NMDA receptor antagonists of all types (GluR competitive antagonists, Gly site competitive antagonists, open channel blockers and selective antagonists acting preferentially on a polyamine site or on the NR 2B subunit of the NMDA receptor) protect against ischemic brain damage 203 .
4. Metabotropic glutamate receptors (mGluRs) and neurodegeneration The predominant effect of Group I GluR activation is excitatory. Agonists, such as 1S, 3R-1-amino-1,3-cyclopentanedicarboxylate and 3,5-dihydroxyphenylglycine, act on mGluR 1 or mGluR 5 . When mGluR agonists are injected focally into the brain, they produce epileptic activity and focal neurodegeneration confirming that Glu is an EAA 204 . This focal stimulation is probably caused by a reduction in several K + conductances producing membrane depolarization with potentiation of NMDA receptormediated conductance changes and excitotoxicity 205 . There is, however, one Ca ++ sensitive K + channel that is o p e n e d b y m G l u R 1 a c t i v a t i o n l e a d i n g t o hyperpolarization 206, 207 . Activation of Group I mGluR contributing to cell death following cerebral ischemia and traumatic brain injury has been supported by research findings. These reports show that Group I mGluR antagonists can be neuroprotective in model systems 25 . A variety of effects have been described in cell cultures. In hippocampal cells expressing Group I mGluR, but not iGluRs, a protective effect of Glu is seen against oxidative stress and against glucose deprivation 208 . In addition, Glu pre-exposure has the effect of up-regulating mGluR 1 and mGluR 3 . In co-cultures of neurons and astrocytes, activation of Group II receptors on astrocytes is neuroprotective via release of a neurotrophic factor, transforming growth factor β [TGF-β] 209, 210 . NAAG, the endogenous mGluR 3 agonist, also is neuroprotective against striatal quinolinate lesions 211 and against NMDA excitotoxicity in mixed cortical cultures 212 . TGF-β and Group II mGluR agonists also protect against apoptosis induced by β-amyloid 213 .
Chronic neurodegeneration
The Glu synapse is a potential target for intervention in a very wide range of neurological and psychiatric disorders including epilepsy, motor neuron disease [MND] , HD, AD, PD, stroke and traumatic brain injury, psychiatric disturbances, and pain 214, 215 . It has been proposed that the neurodegeneration seen in these late onset neurological disorders, is at least partially dependent on endogenous Glu activating NMDA or AMPA receptors.
Motor neuron diseases and amyotrophic lateral sclerosis: Motor neuron disease [MND] 26 may involve defective GluT and enhanced AMPA receptor activation [216] [217] [218] . Therefore, anti-Glu strategies have been proposed and Riluzole has been shown to decrease mortality 219 . Excitotoxicity does play a role in the degeneration of spinal motor neurons in individuals with ALS 220, 221 . In fact low concentrations of Glu determined in cerebrospinal fluid of patients (only 2-fold increase compared with controls) induce apoptosis in cultured spinal motor neurons 222 . AMPA receptors on spinal motor neurons [SPN] are involved in several types of MND 216, 223 and probably mediate their activity through permitting increased intracellular accumulation of Ca ++ 224 . iGluRs are not the only receptor group implicated in the disease, although interpretation of the effect of the mGluR is difficult. Inhibition of mGluR is claimed to have a protective effect 225 , but it also reduces expression of mGluR 2 mRNA in T-cell lymphocytes is seen in individuals with the active disease 226 . The explanation for the differences in these studies probably can be attributed to the cell types examined 227 . In patients with MND, there appears to be a reduction in the expression of mGluR 1 , a glial GluT, in the spinal cord and brain regions showing loss of motor neurons [MN] 228 and defective editing of mRNA encoding the GluR 2 subunit of Glu AMPA receptors in affected MNs from individuals with ALS 229 . The modification of these AMPA receptors aggravates the disease 230 , probably through the increase in free Glu. In addition, mGluRs are also involved in the excitotoxicity. Loss of the mGluR-mediated regulation of Glu transport in chemically activated astrocytes does exacerbate MN toxicity 231 . Huntington's disease: Huntington's disease [HD], which was first described by George Huntington in 1872, involves the extrapyramidal motor system, and is characterized by chorea, a dementia that is progressive, and other psychiatric symptoms 30 . In terms of brain pathology, GABAergic medium spiny striatal neurons are most affected, resulting in atrophy of the caudate nucleus, putamen, and globus pallidus; there is also pronounced atrophy of the cerebral cortex 237, 238 . The neuronal loss in the striatum is accompanied by pronounced gliosis.
The vulnerable striatal neurons contain encephalin, dynorphin, and substance P, and primarily innervate the substantia nigra and globus pallidus. Medium sized spiny neurons containing somatostatin, neuropeptide Y, and NADPH diaphorase, in addition to cholinergic interneurons and parvalbumin containing GABAergic neurons, which are relatively spared 239 . In the cerebral cortex, large neurons in layer VI are the most affected, with smaller amounts of degeneration seen in layers III and V [238] [239] [240] . Neurons may also be lost in the thalamus, zona reticulata of the substantia nigra, superior olive, lateral tuberal nucleus of the hypothalamus, and deep cerebellar nuclei 239, 241 . There is also an overlapping pattern of neurodegeneration of GABAergic efferent projection neurons with the progress of the disease, accompanied by the loss of cannabinoid [CB] receptors throughout the basal ganglia 242 . It has been demonstrated that the underlying cause of HD is the expansion of a CAG repeat sequence in the first exon of a gene on chromosome 4p16.3, which encodes the protein huntingtin [242] [243] [244] . CAG is the codon for glutamine (Q in the single letter code for amino acids) 245 . The normal range for the number of Qs in the polyglutamine tract [polyQ] is between six and 34, with disease being found when polyQ is greater than 40.
Interestingly, within the HD genome, expansion of trinucleotide repeats appears not to be limited solely to the huntingtin gene. The allelic frequency distributions for two other genes containing such repeat sequences (SCA 1 and FRDA) are shifted towards larger alleles compared with healthy controls, which suggests that a common mechanism caused expansion in all three genes 246 . The expanded CAG repeat is transmitted predominantly through the male germ line in humans and transgenic mice, and the size of the CAG repeat was influenced by the sex of the offspring from identical fathers. Thus, male offspring had expanded repeats, whereas the opposite was seen in females. This finding led to the hypothesis that X and Y chromosomal encoded factors influenced embryonic DNA repair and replication 247 . Furthermore, within striatal cells, expansion biased changes were shown to increase with age, suggesting that non-replication based mechanisms may also contribute to CAG repeat instability 248 . Attention to excitotoxicity via the NMDA and Ka receptors in HD has been given [249] [250] [251] [252] and now much of the intracellular signaling cascade underlying excitotoxicity in HD has been pieced together. Key players in excitotoxicity are the NMDA 253 and Ka receptors, post-synaptic density protein 95 (PSDP-95), mixed lineage kinase [MLK] , and cJun-N-terminal kinase [JNK] .
GluR stimulation is involved in MLK l activation 254 , whereas JNK 3 activation has been linked to apoptosis 255 . More neurons display desensitizing AMPA currents in the presence of cyclothiazide [CTZ] , indicating increased expression of "flop" splice variants, whereas the majority of wild-type cells express the "flip" variants of AMPA receptor subunits in R 6/2 mice 256 . NMDA peak currents also are smaller in R 6/2 pyramidal neurons and currents are smaller in the presence of Mg ++ . Altered GluR function could contribute to the changes in cortical output and may underlie some of the cognitive and motor impairments in the R 6/2 animal model of HD 256 . Now the connection between these processes and the roles of huntingtin and excitotoxic proteins is becoming clearer. PSDP-95 is a scaffold protein, which binds to several intracellular proteins and possesses guanylate cyclase activity. It binds via repeat units in its structure, termed PDZ domains, to the NMDA receptor and plays a pivotal role in regulating synaptic plasticity and synaptogenesis 257 . Specifically, PSDP-95 binds to the NR 2 NMDA receptor and Ka receptor, GluR 6 , subunits.
Variant huntingtin with expanded polyQ tracts interfere with the binding of PSD-95 to NMDA and Ka GluR, causing both receptors to become hypersensitive 258, 259 , thereby allowing increased Ca + + influx via specific uptake pathways 260 . In turn, the MLK isoform, MLK 2 261 is activated, causing activation of MAP 4 and MAP 7 kinases and stress signaling kinase [SEK 1 ], and consequently JNK 2 261, 262 . Activated JNK 2 phosphorylates the N-terminal region of c-Jun, which is one half of the transcription factor activator protein AP 1 , thus modulating gene transcription. Activated JNK also phosphorylates the C-terminal region of MLK 2 . This step appears to be crucial in the triggering of apoptotic cell death 30 . Co-transfection of a dominant negative MLK 2 blocks apoptotic cell death induced by variant huntingtins 263 . Alzheimer's disease: The classical neuropathological changes seen in AD include cortical atrophy, loss of cholinergic cells in the nucleus basilis, and regional histopathological changes in the brain 27 . Pathological changes include neuritic plaques, neurofibrillary tangles [NFTs], neuropil threads, and granulovacuolar neuronal degeneration. Neuritic plaques have a central core that i n c l u d e s β -a m y l o i d , p r o t e o g l y c a n s , a p o E , α 1 -antichymotrypsin, and other proteins 264 . Accumulation of β-amyloid activates macrophages and microglia, producing inflammation that further accelerates neuronal damage 265 . The NFTs are paired helical neurofilaments in neuronal cytoplasm that consist of abnormally phosphorylated tau [τ] protein and ubiquitin 27, 264 . In its normal form, τ functions in the assembly and stabilization of microtubules that guide transport of organelles, glycoproteins, and other important materials through the neuron 264 . Although some aspects of AD pathology are found in normal aging, the density of neuritic plaques and NFTs increases as AD progresses and can be distinguished from those of age-matched normal people 265 . AD was once thought to result from a cholinergic deficit alone, but now it is recognized that this view is over simplistic 266, 267 . Studies using human neocortical tissue have shown that multiple neurotransmitters are involved in determining the amplitude of individual postsynaptic currents and, consequently, the electrophysiology of the human cerebral cortex 268 . These neurotransmitters include Glu, DA, NE, and serotonin (5-hydroxytryptamine [5-HT]), and have been shown to be reduced or dysregulated in AD. The interactive regulation of actions of these transmitters complicates our understanding of the control and modulation of neuronal activity, but an understanding of how these processes work together may eventually permit us to understand the mechanism of the progression of AD 269 . Currently, the neurotransmitter systems most studied in t h e p a t h o g e n e s i s o f A D a r e t h e c h o l i n e rg i c a nd glutamatergic systems 27, 270 . In the glutamatergic systems both iGluR and mGluR seem to play a role in AD as the mGluR has been associated with increased amyloid precursors in individuals with AD 271 . However, the relationships among the iGluR and mGluR are probably complex 272 . In sporadic Alzheimer's disease [SAD], Glu and glutamine concentrations fall because it acts a substitute for lack of glucose early in the disease. In fact, Glu-glutamine cycling is found in the brains of individuals who have died showing clinical signs of AD 701 . In contrast, the affect on GluR density is minimal, indicating an excessive activation of the glutamatergic neurotransmitter system, particularly via the NMDA receptor, which can mediate endogenous excitotoxicity 273 . NMDA plays a distinct role in AD 269 . The NMDA receptor serves as a gating switch for the modification of major forms of synaptic plasticity so it plays a crucial role in certain types of learning, memory formation, and the consolidation of short-term memory into long-term memory 274 . It is a large macromolecular complex 275 that requires Glu and the modulatory agent Gly to be present before activation of the receptor can take place 276 .
Mg
++ can gate Glu-activated channels 277 by blocking the NMDA ion channel under the conditions of a resting membrane potential at approximately -70 mV. This block is removed by depolarization of the cell membrane to about -50 mV 276 . Dysregulation of NMDA receptor function has been implicated not only in the pathology of AD 278 , but also in the pathogenesis of various other neurodegenerative disorders 279 . Glu and GluR play an important part in AD 269 . Neuroimaging studies have shown that Glu and glutamine are reduced in the brains of patients with AD 280 , which indicated that the local dysregulation of Glu might contribute to Glu neurotoxicity in AD 269 . One of the primary nonvesicular sources of extracellular Glu in AD appears to arise from a dysfunctional cystine-Glu antiporter 281 . Under normal physiologic conditions, the antiporter is negatively regulated by mGluR and Glu transporters, which ensure that the right amount of Glu is released. In addition, β-amyloid accumulation in AD has been shown to inhibit Na + -dependent Glu uptake through oxidative inhibition of the Glu transporter 282 , which may increase local extracellular concentrations of Glu 283 .
Memantine is a weak Glu antagonist and has been shown to improve learning and memory in animal models and in patients with moderate to severe AD, whereas highaffinity NMDA receptor antagonists may provide an inhibition of NMDA receptors that is too strong for therapeutic benefit 279, 284, 285 . Achieving the optimal balance of Glu stimulation without excitotoxicity is an important goal for achieving the optimal treatment of patients with AD. It is using this concept of balance that memantine, a noncompetitive agonist with a relatively low to moderate affinity for NMDA receptors was developed for some neurodegenerative diseases 286, 287, 291 . It does not bind to the agonist-binding site but instead blocks the open channels in a m a n n e r t h e N M D A r e c e p t o r , a n d i s v o l t a g e dependent 288, 289, 290 . Further elucidation of interactions of the cholinergic and Glu systems is warranted. Although cholinergic and glutamatergic interactions are quite complex, nonclinical experiments have helped us interpret how these complex systems interact 292 . Activation of nicotinic receptors located on presynaptic glutamatergic neurons stimulates Glu release and increases the NMDA receptor activity on postsynaptic neurons 2 92-294 . Activation of presynaptic nicotinic acetylcholine receptors in the presence of extracellular Ca ++ can initiate multiple forms of enhanced glutamatergic synaptic transmission in rat hippocampal neurons, the temporal relationship of which suggests that the loss of the cholinergic synaptic mechanisms that modulate the gain and fidelity of hippocampal synaptic transmission may contribute to the cognitive deficits seen in AD 294 . In addition, our understanding of the role of acetylcholine [ACh] in learning and memory has been further enhanced by studies of human and guinea pig cortical pyramidal neurons 268 . Results from these studies suggest that the long-lasting effects of ACh on specific ionic currents may facilitate Glu-mediated depolarization of human cortical neurons 268, 295 . More recently, it has been suggested that brain inflammation, cholesterol, Glu and other neurotransmitters are interconnected in the pathology of AD 296 . As these interactions become clearer, it may advance our understanding of the molecular mechanisms and pathogenesis of AD.
Multiple sclerosis and inflammatory diseases of the CNS: Multiple sclerosis [MS] is the most common disabling neurological condition of European, North American, Australian and other temperate climates. The disease is thought to involve CNS autoantigen-directed T-lymphocytes acting in concert with a genetically determined susceptibility and exposure to environmental induction factors 297 . Still there remains a lack of fundamental knowledge on the primary etiology of MS and a paucity of treatments to alleviate symptoms and ultimately improve quality of life for the patient.
The development and refinement of the inducible animal disease experimental autoimmune encephalomyelitis [EAE] has provided a reliable model for the study of MS offering pathological and neurological features of striking similarity to the human condition 298 . This model provides the opportunity to evaluate potential new therapies for MS treatment and explore novel approaches to drug design, identify new targets, and add to the growing number of drugs in clinical trials 299 . The search for compounds with the ability to modify the onset and development of EAE has invariably focused on immunomodulatory agents 3 0 0 . As elevated Glu concentrations have been seen in MS patients 29 and Glu excitotoxicity has been used as a model of MS 301 , Glu and its receptors seem a relevant focus of research.
Over the last few years, a group of Glu-related compounds have emerged, with the ability to dramatically improve the course of EAE but without apparent immunosuppressive activity. These compounds have been implicated in the pathogenesis of neuroinflammatory disease by interactions with iGluRs NMDA, AMPA and Ka [302] [303] [304] [305] . Hence, the discovery of NMDA and AMPA receptor involvement in both EAE and MS offers a plausible association between the receptors, Glu, and development of both diseases.
As several studies have demonstrated Glu involvement in the pathology of EAE, and also MS 306 , the Glu antagonist amantadine has been shown to reduce the relapse rate in individuals with MS 307 . Enhanced concentrations of the agonist may result from malfunctioning of activated astrocytes normally efficient at controlling excess Glu through regulation of the metabolizing enzymes Glu dehydrogenase and Glu synthetase. These enzymes become down regulated during inflammatory conditions such as EAE 233, 308 . The alternative pathogenesis could be the lack of a GluT produced by oligodendrocytes 309, 310 . Regardless of the exact mechanism, there is an alteration of the Glu homeostasis that does correlate with oligodendrocyte and axonal damage 311 . A mechanism via the actions of cyclooxygenase-2 [COX 2 ] and inducible nitric oxide synthase [iNOS], both of which have been located in MS lesions, might account for the increase in CNS Glu concentrations during the inflammatory phase of relapsing-remitting disease 312 . C O X 2 -d e r i v e d p r o s t a n o i d s , w h i c h e x i s t a t h i g h concentrations in EAE and MS CNS tissues [313] [314] [315] , stimulate Glu release from CNS-derived cells 316, 317 . In addition, NO, from iNOS, can increase COX 2 318 , plus ROS 319 , to react with NO to produce peroxynitrite 320 that inactivates the Glu transporters 321, 322 . These ROS directly damage myelin, oligodendrocytes, and axons 323 . Understanding the mechanism of action of the Glu system on EAE has led to develop treatment modalities for MS. Results to date have been largely negative and evidence for a neuroprotective role of Glu antagonists in neurodegenerative diseases is lacking 275 . Similarly, despite efforts to develop compounds that act by altering the metabolism of Glu, no such drugs have been produced.
Parkinson's disease: Parkinson's disease [PD] is another common and debilitating neurodegenerative disorder, affecting 1% of the population over 65 years of age. Pathologically it is characterized by a progressive loss of the dopaminergic neurons of the substantia nigra pars compacta [SNC] and the presence of intraneuronal cytoplasmic inclusions termed Lewy bodies. The loss of these neurons causes degeneration of the nigrostriatal tract, resulting in the classic motor symptoms of PD, namely akinesia or bradykinesia, tremor, muscle rigidity and postural instability 324 . Currently the treatment of PD is primarily symptomatic aiming to replace lost DA using DA replacement therapy. Whilst this approach is effective in the early stages of PD, as the disease progresses the efficacy of the currently available drugs decreases and side effects are common. Furthermore these treatments do nothing to halt the progression of the disease. Current evidence suggests that these altered responses involve activation of signal transduction cascades in striatal medium spiny neurons linking dopaminergic to co expressed iGluRs of the NMDA and AMPA classes 28 . These intraneuronal signaling pathways appear capable of modifying the phosphorylation state of NMDA and AMPA receptor subunits; resultant sensitization enhances cortical glutamatergic input, which in turn modifies striatal output in ways that compromise motor behavior. Regulation of these spiny neuron GluR can also be affected by the activation state of co expressed non-dopaminergic receptors 325 , which sheds new insight into molecular mechanisms contributing to the integration of synaptic inputs to spiny neurons 28 . They also suggest novel approaches to the pharmacotherapy of extrapyramidal motor dysfunction. Thus, current research has focused on identifying novel nondopaminergic therapies for use in both symptomatic and neuroprotective strategies in PD, such as LY503430 326 . Altered glutamatergic neurotransmission and neuronal metabolic dysfunction are central to the pathophysiology of PD 327 . The SNC is particularly exposed to oxidative stress and toxic and metabolic insults 328 , resulting in mitochondrial dysfunction 327 . Recently, the recognition that Glu that have been implicated in PD, particularly in the basal ganglia 329 , has focused research on the neuroprotective and symptomameliorating properties of mGluR 330 , G-protein-coupled GluR ligands 324, 329, [331] [332] [333] . In contrast, Group-I mGluRs (mGluR 1 and 5 ) need to be antagonized in order to evoke protection 334 antagonists, and drugs acting on 5-HT 2A , α 2 -adrenergic, adenosine A2A and CB 1 receptors may be helpful 335 . Initially, all neuroprotective mGluR ligands were analogues of L-Glu. Those compounds were valuable to demonstrate protection in vitro, but showed limited applicability in animal models, particularly in chronic tests, due to low blood-brain-barrier penetration 336 . Recently, systemically active and more potent and selective ligands became available, e.g., the Group-II mGluR agonists LY354740 and LY379268 or Group-I antagonists like MPEP (mGluR 5 -selective) and BAY36-7620 (mGluR 1 -selective) 3 3 4 . It has now been shown that mGluR 5 antagonism produces strong anti-dyskinetic effects in an animal model of PD through central inhibition of the molecular and neurochemical underpinnings of L-3,4-dihydroxyphenylalanine [L-DOPA]-induced dyskinesia 337 . A wide range of antagonists of Group I and agonists of Group II and III mGluRs continue to be investigated in vivo following 6-hydroxydopamine lesioning of the nigrostriatal tract in rodents 125 . Studies using focal drug administration have yielded very promising results, which have been inconsistent in mice but show significant neuroprotective effects in primates 328 . A potential role for excitotoxic processes in PD has been strengthened by the recent observations that there appears to be a mitochondrially encoded defect in complex I activity of the electron transport chain 328 . An impairment of oxidative phosphorylation enhances vulnerability to excitotoxicity 328 . SNC neurons possess NMDA receptors and there are glutamatergic inputs into the substantia nigra area [SNA] from both the cerebral cortex and the sub thalamic nucleus. As in other cases of Glu excitatory toxicity, activation of EAA receptors results is an influx of Ca ++ followed by activation of neuronal NOS, which can then lead to the generation of peroxynitrite. Consistent with such a mechanism, studies of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP] neurotoxicity in both mice and primates have shown that inhibition of neuronal NOS exerts neuroprotective effects. These results raise the prospect that EAA antagonists for neuronal NOS inhibitors might be useful in the treatment of PD 328 . A reduced capacity to cope with metabolic demands, possibly related to impaired mitochondrial function, might render the SNA highly vulnerable to the effects of Glu, which acts as a neurotoxin in the presence of impaired cellular energy metabolism. In this way, Glu may participate in the pathogenesis of PD 338 . Degeneration of DA SNCs is followed by striatal dopaminergic denervation, which causes a cascade of functional modifications in the activity of basal ganglia nuclei. As an excitatory neurotransmitter, Glu plays a pivotal role in normal basal ganglia circuitry. With nigrostriatal dopaminergic depletion, the glutamatergic projections from sub thalamic nucleus to the basal ganglia output nuclei become overactive and there are regulatory changes in GluRs in these regions. There is also evidence of increased glutamatergic activity in the striatum. In animal models, blockade of GluRs ameliorates the motor manifestations of PD. Therefore, it appears that abnormal patterns of glutamatergic neurotransmission are important in the clinical signs and symptoms of PD.
Studies using methamphetamine and MPTP reinforce a link between Glu-mediated excitotoxicity and degeneration of DA cells 339 . Both compounds are thought to create a metabolic stress 328, 339 . In mesencephalic neuronal cultures, DA active cell loss produced by 3-NPA or malonate was potentiated by NMDA and prevented by MK-801 339 . In vivo, striatal DA active neuronal loss produced by intranigral infusions of malonate was also potentiated by intranigral NMDA and prevented by systemic MK-801, supporting the hypothesis of NMDA receptor involvement in degeneration of dopamine active neurons. This effect is likely to occur in the SNA rather than in the striatum 339 .
Other neurological conditions
Cerebral ischemia (stroke) and traumatic brain injury: Stroke and neurotrauma mediate neuronal death through a series of events that involve multiple interdependent molecular pathways. It has been suggested hypoxia triggers these pathways following elevations in extracellular EAAs, primarily Glu 340 . Increased activation of iGluR also has been implicated in the pathophysiology of traumatic brain [340] [341] [342] [343] [344] and spinal cord injuries 345, 346 . In addition, mGluRs participate broadly in the regulation of Glu neurotransmission 48 , yet their role in post-traumatic CNS injury has been largely unexplored.
There has been limited research to address a possible role for mGluR in modulating neuronal death after various non-traumatic insults. To a certain extent, Groups I and II mGluR have contrasting actions. Group I receptors (mGluR 1,5 ) may potentiate neuronal excitation and excitotoxicity 14, 347, 348 , possibly through positive modulation of NMDA receptor activity 349 . Group II receptors (mGluR 2/3 ) may exert a protective effect 347, 350 possibly through presynaptic inhibition of Glu release 14, 351, 352 . Because of these apparently opposing actions, and the fact that more discriminating agonists and antagonists are not yet available, it is not surprising that data have been less than conclusive with regard to the role of mGluR in neuronal death. Indeed, the cyclic Glu analog, 1S,1R-1-aminocyclopentane-1,3-dicarboxylic acid [1S,1R-ACPD], which is an agonist at both Group I and Group II receptor sites contributes to or protects against cell death 204, 205, [352] [353] [354] [355] [356] . It appears as though neuroprotection by glial mGluR are mediated by transforming growth factor β [TGFβ] 212 . The synthesis of phenylglycine derivatives has permitted differentiation of the activity of various mGluR groups through comparison of the activities of selected compounds 351 . However, differentiation of receptor subtypes within these groups has remained problematic 17 . NMDA and AMPA receptor antagonists have been shown to be powerful neuroprotective agents in animal models of stroke 203 . However, NMDA receptor mediated excitotoxicity can contribute to cerebral hypoxia to ischemia 357 . In permanent or reversible occlusion of the middle cerebral arteries, these antagonists consistently reduce the volume of cortex that is infarcted for 24 h for one or more weeks later. Interestingly, they do not protect the striatum following ischemia 358, 359 . However, it is possible that AMPA receptor antagonists reduce cortical and white matter damage in vitro and in vivo 360 . Spinal cord injury often damages the axons of cordprojecting central neurons 361 , and initiates a cascade of biochemical events that lead to an increase in the extracellular Glu concentrations 362 . Rat rubrospinal neurons have been used as a model to examine their excitatory input following upper cervical axotomy. Anterograde tracing shows that the primary afferents from the cerebellum terminated in a pattern similar to that of control animals. Ultrastructurally, neurons in the injured nucleus are contacted by excitatory synapses of normal appearance, with no sign of glial stripping. Since cerebellar fibers are glutamatergic, the expression of iGluR subunits GluR 1-4 and NR 1 have been examined for AMPA and NMDA receptors in control and injured neurons using immunolabeling methods 361 . In control neurons, GluR 2 appears to be low compared with GluR 1 , GluR 3 , and GluR 4 , while NR 1 labeling was intense.
Following unilateral tractotomy, the levels of expression of each subunit in axotomized neurons appears normal, with the exception that they are lower than those of control neurons of the non-lesioned side at 2-6 days post injury. These findings suggest that axotomized neurons are only temporarily protected from excitotoxicity 361 . This is in sharp contrast to the responses of central neurons that innervate peripheral targets, in which both synaptic stripping and reduction of their iGluR subunits persist following axotomy 361 . The absence of an injury-induced trimming of afferents and stripping of synapses and the lack of a persistent down regulation of postsynaptic receptors might enable injured cord-projection neurons to continue to control their supraspinal targets during most of their post injury survival. Although these events may support neurons by providing trophic influences, it nevertheless may subject them to excitotoxicity and ultimately lead to their degenerative fate 344, 363 . The neuroprotection of the Glu system is greatest if the antagonist, such as an AMPA antagonist 364 is given close to the time of onset of the ischemia, as efficacy is diminished with delay, and protection usually disappears with drug administration at 90-120 min post-arterial occlusion. It has been suggested that targeting the AMPA receptor unit GluR 2 would be a useful strategy for stroke therapy 364 , although other authors are less impressed with efficacy of novel NMDA antagonists 363 . Whereas most AMPA type Glu channels are Ca ++ impermeable, an evolving body of evidence supports the contention that relatively unusual Ca ++ permeable AMPA channels might be crucial contributors to injury in these conditions. These channels are preferentially expressed in discrete neuronal subpopulations, and their numbers appear to be up regulated in ALS and stroke. In addition, unlike NMDA channels, Ca ++ permeable AMPA channels are not blocked by Mg ++ , but are highly permeable to another potentially harmful endogenous cation, zinc [Zn ++ ]; hence, targeting these channels might provide new avenues in the treatment of some neurological diseases 363, 364 . Administration of the AIDA (Group I mGluR antagonist), LY 367385 (mGluR specific antagonist), or MPEP (mGluR 5 specific antagonist) in rats following injury at T10 showed that AIDA and LY 367385-treated animals had improved locomotor scores, and LY 367385 potentiated the development of thermal hyperalgesia 362 . MPEP had no effect on locomotor recovery or mechanical allodynia, but attenuated the development of thermal hyperalgesia. AIDA and LY 367385 treatment resulted in a significant increase in tissue sparing at four weeks following injury compared with the vehicle treated control group 362 . These nonclinical data, and similar data for rodent models of traumatic brain injury, have led to major clinical trials of NMDA receptor antagonists in stroke and in head injury 363 . Unfortunately, few of the trials have shown therapeutic benefit as the adverse effects have far exceeded the therapeutic benefits. Adverse events involved cardiac arrhythmias, hypotension, hypertension and cognitive side effects. AMPA antagonists that were shown to be effective in animal models initially have proved unsuitable for clinical trial, but several compounds under development are likely to go forward to clinical trial in the near future.
Glu plays an important role in reperfusion injury following ischemia. Glu excitotoxicity, oxidative stress, and acidosis are primary mediators of neuronal death during ischemia and reperfusion 344 . Astrocytes influence these processes in several ways. Glu uptake by astrocytes normally prevents excitotoxic Glu elevations in brain extracellular space, and this process appears to be a critical determinant of neuronal survival in the ischemic penumbra 365 . Conversely, Glu efflux from astrocytes by reversal of Glu uptake, volume sensitive organic ion channels, and other routes may contribute to extracellular Glu elevations.
Gly and D-serine, both of which are transported by astrocytes, modulate Glu activation of neuronal NMDA receptors. D-serine production is localized exclusively to astrocytes 365 . Astrocytes influence neuronal antioxidant status through release of ascorbate and uptake of its oxidized form, dehydroascorbate, and by indirectly supporting neuronal glutathione metabolism. In addition, glutathione in astrocytes can serve as a sink for NO and thereby reduce neuronal oxidant stress during ischemia 365 .
pharmacologic, biochemical and anatomical evidence has been accumulated over the last several decades firmly implicating the NMDA and AMPA/Ka iGluR and mGluRmediated mechanisms in epileptic seizures [367] [368] [369] . Excitatory glutamatergic mechanisms are involved during both acute, transient, evoked seizures and long-term, adaptive cellular plasticity associated with epileptogenesis in chronic epilepsy models such as amygdala-kindled rats or rats with spontaneous, recurring seizures after an early episode of induced status epilepticus 370 . Recently, seizure activity has been shown to change Glu and GluR distribution 371 , in particular mGluRs 372 . Thus, epilepsy would seem an excellent target on which Glu may excite foci of neurons to produce seizure activity via iGluR and mGluR 373 . Therefore it is not surprising to note that NMDA and AMPA receptor antagonists are powerful anticonvulsants in a wide range of animal models of epilepsy 374 . These antagonists decrease the concentration of mGluRs 375 , and, therefore, the use of GluRs in modulation of epilepsy should be theoretically possible.
Pure NMDA or AMPA receptor antagonists have yet to have much clinical history, although several agents that show such properties mixed with other actions have been introduced e.g., felbamate (NMDA antagonism) and topiramate, (AMPA antagonism), or are under trial e.g., remacemide, (NMDA antagonism). Antagonists at Group I and agonists at Group III mGluRs also appear to be potential candidates for clinical trial in epilepsy 369, 376, 377 . Regardless of the progress, GluR still remains a strategic target for the treatment of epilepsy 378, 379 . Our understanding of the molecular basis of epilepsy is still limited. Genetically, a number of mutations underlying naturally occurring epileptic syndromes have been identified in animals and humans. These mutations mainly involve ion-channel defects, which include voltage-sensitive Ca ++ , K + or Na + channels, Na + -hydrogen exchangers and nicotinic cholinergic receptors 380, 381 . It is questionable as to whether mutations directly involving glutamatergic transmitter system components (Glu, iGluR, mGluR, and GluT) are present 374 . Epilepsy investigators have theorized that a dysfunction in glial cells, and not in neurons or synapses, may be the initiating cause of epilepsy 382 . This suggestion has been based on several observations where robust reactive gliosis is necessary to induce posttraumatic epilepsy 383 . Astrocytes play a crucial role in ion homeostasis and, therefore, in neuronal excitability 384 . Manipulation of glial cell volume and, thus, of extracellular volume affects neuronal hyper synchronicity, indicating that the cell surface and possible the cytoplasm are needed for hyper synchronicity 385, 386 . Astrocytes have a direct role in the r e g u l a t i o n o f s y n a p t i c s t r e n g t h a n d n e u r o n a l excitability 387, 388 . Thus, evidence has been steadily accumulating that a dysfunction in the astrocytic compartment can lower seizure threshold and precipitate seizures 382 . Regardless of the site of initiation, seizures can be provoked in epileptic and non-epileptic animals and humans by a wide number of glutamatergic molecular mechanisms. Despite the varied primary pathology in epileptic seizures, the mechanisms involved in generating and spreading epileptic discharges converge on a common cellular pathology in which the excitatory glutamatergic system plays a key role.
Psychiatric disturbances: It is recognized that the acute signs of PCP intoxication are reversed in the rat by the Group II mGluR agonist LY 354740 389 . It is also suggested that standard antipsychotic drugs such as haloperidol and clozapine may be effective partially through NMDA receptor potentiation 390 . Similarly, a Gly site NMDA antagonist, L-701324, has a neuroleptic-like action in several animal models of psychosis 391 . Schizophrenia: Impairments in certain cognitive functions mediated by the dorsolateral prefrontal cortex, such as working memory, are core features of schizophrenia. These cognitive functions in schizophrenia have been associated with a pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens 392 . Several neurochemical hypotheses have been proposed to account for the origin and symptoms of schizophrenia, including abnormal dopaminergic, GABAergic, and glutamatergic neurotransmission [393] [394] [395] [396] [397] [398] [399] . Pharmacological studies showing that NMDA receptor antagonists, modulated by mGluR 1 and mGluR 5 such as PCP and ketamine might play a role in schizophrenia 400 , as many of the psychotic signs and symptoms of schizophrenia can be seen normal exposed to these drugs 399, [401] [402] [403] [404] . A dysregulated glutamatergic state in schizophrenia has been characterized by abnormal glutamatergic neurotransmission in the hippocampus, entorhinal cingulate, and prefrontal cortices 394, [405] [406] [407] [408] [409] involving the glutamatergic system in learning, memory, emotion, and behavior 398, 410, 411 . A bn o r m a l G A B Ae r g i c ne u r o t r a n s m is s i o n i n schizophrenia includes lower GABA uptake and release in the frontal cortex [412] [413] [414] , lower glutamic acid decarboxylase activities and mRNA in some brain regions and neurons [415] [416] [417] [420] [421] [422] , and less GABA transporter protein 1 [GABATP 1 ] in axon terminals of chandelier neurons 423 . Thus, in addition to glutamatergic dysfunction in schizophrenia, there are concurrent defects in GABAergic neurotransmission 414, 419, 424 . Hypofunction of the NMDA-receptor also may contribute to the pathophysiology of schizophrenia 425 . Clinical studies using the NMDA and Gly-site agonists Gly and D-serine 426 indicate significant improvements in negative and cognitive symptoms of schizophrenia. Therefore, reduced activation of the Gly binding site of the NMDA receptor probably contributes substantially to the ongoing clinical signs and symptoms. Since Gly is not actively transported across the blood brain barrier, plasma levels of this compound are in equilibrium with brain levels 427, 428, 429 . Elevated levels of homocysteine [HC] , which acts in part as an NMDA-Gly site antagonist 430 , may also contribute to symptom development in schizophrenia as high HC p l a s m a l e v e l s a r e a n e s t ab l i s h e d r i s k f a c t o r f o r cardiovascular, cerebrovascular, and Alzheimer's disease and have been observed in schizophrenia 431 . It has been suggested that the management of clinical symptoms of schizophrenia might be assisted by the administration of folic acid, pyridoxine, and B12, which help reduce HC levels 432 . Structural and functional pathology have been detected in the thalamus in patients suffering from schizophrenia 444 . Lower thalamic cell numbers and volume are not as a reliable indicator of schizophrenia in comparison to decreased thalamic metabolism [433] [434] [435] [436] [437] [438] [439] [440] [441] [442] [443] because most thalamic afferents and efferents are use Glu as a neurotransmitter [444] [445] [446] and pharmacological evidence implicates glutamatergic dysfunction in schizophrenia.
NMDA, AMPA, Ka iGluRs along with mGluRs make up the four families of GluRs that are expressed in the thalamus 13, 447 , and NMDA receptor abnormalities are most often associated with schizophrenia [401] [402] [403] [404] 448, 449 . Adjunct treatment with conventional antipsychotics of agonists and partial agonists of the Gly coagonist site of the NMDA receptor has been reported in some studies to ameliorate negative psychotic symptoms [450] [451] [452] [453] [454] [455] . NMDA receptor hypoactivity is associated with schizophrenia either due to primary defects in NMDA receptors or from dysfunction of a GluR family [456] [457] [458] [459] [460] [461] [462] [463] , and secondarily affects activation of AMPA receptors. Interestingly, AMPA receptors are extensively co localized with NMDA receptors at glutamatergic terminals 464 . In addition, pre-and postsynaptic mGluRs affect NMDA receptor-mediated neurotransmission 389, 465, 466 , a dysfunction of which could mimic abnormal NMDA receptor activity 467 . A recent focus of schizophrenia research is the disruption of white-matter integrity 468 . This research using magnetic transfer imaging and diffusion tensor imaging, which showed differences in white-matter integrity and tract coherence in persons with schizophrenia compared to controls 469 . Oligodendrocytes, in particular, have been the subject of increased study after gene microarray analyses revealed that six myelin-related genes specific to oligodendrocytes have decreased expression levels in schizophrenia. These cells have also been shown to be decreased in number in the superior frontal gyrus of subjects with schizophrenia 468 . Stress-related conditions: Stress-related psychiatric disorders, such as depression and anxiety disorders, are prevalent and are of enormous public health concern 470 . The hypothalamic-pituitary-adrenal [HPA] axis is the key regulator of the stress reaction in the fetus, child and adult 471 . Dysregulation of this axis has been shown to play a central role in the pathophysiology of anxiety and depressive disorders [472] [473] [474] [475] [476] [477] [478] , providing evidence that the glutamatergic system, and in particular mGluRs, play a critical role in the pathophysiology of stress-related behavioural disorders [479] [480] [481] [482] . In fact, Group-III mGluR subtypes (including mGluR 4,6-8 ) have been implicated in anxiety and depression [483] [484] [485] [486] [487] [488] . (1) Depression: There is now doubt that Glu plays a role in depression and antidepressant activity. In fact, a single intravenous dose of an NMDA receptor antagonist is sufficient to produce sustained relief from depressive symptoms 480 . NMDA receptor antagonists, Group I mGluRs (mGluR 1 and mGluR 5 ) antagonists, and positive modulators of AMPA receptors have antidepressant-like activity in a variety of nonclinical models 489 , which may be initiated by Glu interaction with NOS 490, 491 . There is extensive colocalization of EAA and monoamine markers in nuclei such as the locus coeruleus and dorsal raphe, which are central to depression; therefore it is likely that regulation of monoaminergic and EAA neurotransmission and antidepressant effects are interdependent 489 . Certainly, there is evidence implicating disturbances in Glu metabolism, NMDA, and mGluR 1,5 receptors in depression and suicidal tendencies 480 .
(2) Anxiety: Anxiety disorders include panic disorder, post-traumatic stress disorder [PTSD], obsessive compulsive disorder [OCD], specific phobias, and others 492 . Nonclinical studies have shown that the amygdala plays a key role in fear circuitry, so it is not surprising that abnormalities in amygdala pathways can affect the acquisition and expression of fear conditioning. Drugs such as NMDA antagonists, and blockers of voltage-gated Ca ++ channels in the amygdala, may block these effects 493, 494 . Amnesia: Memory loss is characteristic of Glu excitotoxicity as seen in DMA poisoning, so targeting Glu's action at AMPA receptors may be useful in addressing amnesia. D-cycloserine, a partial agonist at the Gly site of the NMDA receptor, has been shown to enhance performance in various animal memory tasks 32 , In addition to demonstrating memory enhancement in animal models 495 , elderly humans are also benefited 496 . Pain: In addition to NE effects, hyperalgesia clearly involves NMDA receptors in the spinal cord, and peripheral m Gl uR s a re t ho u gh t to m e di a t e a c o m po n e n t o f hyperalgesia 497, 498 . HIV-1, or immune-related, toxins lead indirectly to the injury or death of neurons via a potentially complex web of interactions among microglia, astrocytes, and neurons 502 . Astrocytes seem to manage the interaction of HIV-infected macrophages, microglia, or monocytes, resulting in a secretion of substances that potentially contribute to neurotoxicity, such as eicosanoids and HIV-1 envelope protein gp120 503 . Regardless of the mechanism of a action, it still is the critical influx of Ca ++ that kills the neurons. These secreted substances lead to increased Glu release or decreased Glu reuptake; hence, free Glu becomes more abundant. Macrophages also induce the release of the Glulike agonist quinolinate. 512, 513 . In fact, the expression of GluR genes has defined the localization of GluR 1 through GluR 7 mRNAs in the mammalian retina 514 . The retina is composed of seven cell types, which are organized into layers, with nuclear layers containing somata separated by plexiform layers filled with processes. Absorption of light initiating the signal transduction cascade through the retina is done at the level of the most distal cells-photoreceptors 515 . Photoreceptors are presynaptic to horizontal and bipolar cell dendritic processes in the outer plexiform layer [OPL] 516 . Bipolar cells relay the signal to the inner retina, where they are presynaptic to amacrine and ganglion cells in the inner plexiform layer [IPL] . These amacrine cells contain AMPA-, NMDA-, GABA-, and Gly activated currents [517] [518] [519] [520] [521] and they are important in the regulation of mGluR 522, 523 . Ganglion cell axons form the optic nerve and transmit the signal to the brain. It is the connections between photoreceptor, bipolar, and ganglion cells that form the vertical transduction pathway through the retina 516 .
Glu is the neurotransmitter released between elements in this pathway and can be toxic 524 in certain conditions, as described below. The pathway is modulated in the OPL through electrical 525 and GABAergic synapses arising from neighboring horizontal cells 526 . Both synaptic layers of the retina contain Group I mGluR: mGluR 1α and mGluR 5α 527 . Glycinergic and dopaminergic interplexiform cells also provide inputs to the OPL 528, 529 , whereas in the IPL, inhibitory GABAergic and glycinergic inputs from amacrine cells modify bipolar-to-ganglion cell signaling 516 . In addition to neurons, Muller glial cells are also present. Muller cells, which are the radial glial cells of the retina, extend the width of the retina and play a role in the removal of excess Glu 530 . Neuronal activity appears paradoxical in the retina, but Glu is believed to be the major excitatory neurotransmitter at this site. Neurons characterized by their response to light, with ON-type cells depolarizing in response to a light stimulus and OFF-cells hyperpolarizing to light or depolarizing in the dark. Signal transduction to both ON and OFF pathways is initiated by photoreceptors, which release Glu in the absence of a stimulus, i.e., the dark, depolarizing OFF-cells and hyperpolarizing ON-cells 22 . High levels of the Group II mGluR are expressed in these cells 531, 532 . In fact, the separation between ON-and OFF-pathways express different types of postsynaptic GluRs, pathways that are also morphologically distinct with the processes of OFFamacrine, ganglion, and bipolar cells [533] [534] [535] [536] [537] . As discussed earlier, Glu can be toxic in the eye in elevated concentrations 524 probably through excitotoxic activity 538 as can be seen with excess Gly 539 . GluRs are important to the expression of the excitotoxic effects of Glu and Gly, although retinal ganglion cells do not appear to be as sensitive to excitotoxicity as are other neural cells in the eye 540 . Neuroactive Glu is stored in synaptic vesicles in presynaptic axon terminals 541 and is incorporated into the vesicles by a Na + -independent, ATP-dependent GluT located in the vesicular membrane [541] [542] [543] . GluTs maintain the concentration of Glu within the synaptic cleft at low levels, preventing Glu-induced cell death [544] [545] [546] [547] . Glial Glu rapidly breaks down into glutamine 530 , which is then exported and incorporated into surrounding neurons 548 . Neurons can then later synthesize Glu from this glutamine 548, 549 . Neuronal Glu activity is not the only method of Glu cycling and concentration management. Oligodendrocytes are important and act as a negative regulatory activity, but are harmed by excessive Glu 149 . It is interesting to note that GluR activity is necessary for normal development of tectal cells 550, 551 , probably through NMDA types of GluR 552 . Retinal photoreceptors, bipolar cells, and ganglion cells are can be visualized microscopically as they are Glu immunoreactive 68,71, [553] [554] [555] [556] [557] [558] [559] . and surrounding cells can also display weak labeling with Glu antibodies 553, 554, [558] [559] [560] . However, neurons are believed to release GABA, not Glu, as their neurotransmitter 561 , suggesting the weak Glu labeling reflects the pool of metabolic Glu used in the synthesis of GABA 558, 560 . Finally, GluRs are important in the visual cortex, where mGluRs have been shown to be important in processing of visual information in the superior colliculus 562 .
(1) Ischemia: Glu is an important component to the pathogenesis and pathology of ocular ischemia 563 , more specifically there is a decrease in Glu-Asp transporter [GLAST] in ocular ischemia 564 . The GluR subtypes involved in organ specific ischemic responses varies depending on the tissue, e.g., in hippocampal neurons a subunit-specific down regulation of GluR 2 precedes the actual neurodegeneration, whereas the retina does not 565 . Retinal ischemia and reperfusion changes the quantitative expression of the different AMPA-type GluR subunits 566 , affecting excitatory synaptic transmission in the inner retina 227 . In fact, excitotoxic mechanisms are involved in ischemia-induced neuronal death in the retina, and ROS generated under conditions of ischemia may be a primary cause of retinal damage 567 . A number of GluR antagonists have been used experimentally to show that some do protect against ischemia-induced damage 568 . Ischemia-induced axonal loss in large retinal ganglion cell axons is similar to that seen in glaucoma 569 . (2) Glaucoma: Although raised intraocular pressure [IOP] is a significant risk factor for developing glaucoma, there is no set threshold for IOP that causes glaucoma. One person may develop nerve damage at a relatively low pressure, while another person may have high IOP for years and yet never develop damage. Untreated glaucoma shows a characteristic pattern of optic neuropathy leading to permanent damage of the optic nerve and resultant visual field loss, which can progress to blindness 570, 571 . Increased IOP has been shown to increase Glu in the optic nerve 572 , which may implicate Glu and GluRs in the development of glaucoma. However, retinal ischemia is more central to the understanding of the pathogenesis of glaucoma, hence neuroprotection in the face of ischemia would be of great assistance in the clinical treatment of the disease. It is for this reason that management of glaucoma is directed at the control of IOP, with therapy preventing the death of ganglion cells as the main goal of treatment.
Not all types of retinal ischemia lead to the pathologic findings seen in glaucomatous retinas or to cupping in the optic disk area 573 . It appears as though EAA transporter EAAT-1 is down regulated resulting in the elevated Glu levels that exist in the vitreous humor of patients with glaucoma 574 . For this reason, compounds that block NMDA receptors to prevent the action of the released Glu or substances that interfere with the subsequent cycle of events that lead to cell death via influx of Ca ++ and the generation of ROS have been shown to be neuroprotective 567 e.g., betaxolol 573 . (3) Diabetic retinopathy: Diabetic retinopathy is a serious consequence of diabetes mellitus. Diabetic retinopathy is a major cause of disability with an estimated 40% of adults over the age of 40 years having some form of diabetic retinopathy and 8% having vision-impairing diabetic retinopathy 575 . Recent work suggests that elevated glucose may alter Glu neurotransmission and Ca ++ homeostasis in the retina, which may have implications for the mechanisms of vision loss in diabetic retinopathy 576 . GluRs have been shown to affect altered synaptic transmission in the IPL and OPL in the diabetic retina 577 , and are implicated in ocular Glu toxicity 578 . Recently, the receptors involved in this alteration have been identified as AMPA GluR channels 576 . Using primary retinal cell cultures, high glucose was shown to significantly decreased the protein content of GluR 1 and GluR 6,7 subunits and increased the protein content of GluR 2 and Ka 2 subunits. It also decreased Ca ++ permeability through AMPA receptorassociated channels. Hence elevated glucose alters neurotransmission via alteration of Glu homeostasis in addition to ischemia resulting from the later stages of the disease.
Ear: Evidence has accumulated over the years supporting Glu as the primary neurotransmitter used by hair cells in afferent cochlear neurotransmission 579 . GluRs are involved in excitatory neurotransmission at the first auditory synapse between the inner hair cells and the spiral ganglion [SG] neurons. Fast synaptic transmission in the cochlea is mainly mediated by desensitizing AMPA receptors 580 and Group I mGluR (mGluR 1,5 ) 581 , which are slower in their excitation were pharmacological specificity and quickly desensitized.
In the cochlea, excitotoxicity may occur in two pathological conditions: anoxia and noise trauma 582 . The lesions are characterized by a two-step mechanism. Firstly, an acute swelling, which primarily depends on the AMPA and Ka type of receptors, together with a disruption of type I afferent dendrites, which are postsynaptic structures, resulting in a loss of function. Within the next five days, synaptic repair may be observed with a full or a partial recovery of cochlear potentials. The second phase of excitotoxicity, which may develop after strong or repetitive injury, consists of a cascade of metabolic events triggered by the entry of Ca ++ , which leads to neuronal death in the SG 583 . Ongoing experiments in animals, tracking the molecular basis of both these processes, preempt the development of new strategies to help neurites to regrow and reconnect properly, and to prevent or delay neuronal death in the SG. Human applications should follow, and a local trans tympanic strategy against cochlear excitotoxicity may, in the near future, prove to be helpful in ischemic-or noise-induced sudden deafness, as well as the related tinnitus 584 . Inhibiting mGluRs in the cochlea does not significantly affect the hearing threshold. In contrast, blocking mGluRs lowers the amplitude of compound action potentials at louder sound levels and reduced the noise-induced temporary threshold shift, indicating that the cochlea is more resistant to noise-induced temporary hearing losses without the activation of metabotropic glutamate receptor inhibitors [mGluRIs] in SG neurons 581, [585] [586] [587] . The expression of synaptic NMDA receptors in the auditory cortex is dynamic and is bidirectionally regulated by auditory activity 588 . Interestingly, GABA is also active at this site. Here the GABAergic component of the olivocochlear system contributes to the long-term maintenance of hair cells and neurons in the inner ear 589, 590 . Disease entities relating to ear function that have been investigated include vomiting, vertigo and tinnitus. Vomiting and vertigo are dependant on AMPA and NMDA GluRs. Antagonism to GluR stimulation has a damping effect of GABA 591 . Salicylate, the active component of aspirin, is known to induce tinnitus. However, the site and the mechanism of generation of tinnitus induced by salicylate remain unclear, but it is thought that salicylate induces tinnitus through activation of cochlear NMDA receptors 592 .
Endocrine
GluRs have been identified in endocrine tissues including the endocrine pancreas, pituitary, pineal gland, and adrenal gland 44, 64, 73, 77, 79, 84, 85, [593] [594] [595] [596] [597] . The identification of these GluR has not yet been translated into their response to disease states. Probably the most hopeful use of GluRs in disease lies in their role in pancreatic function and diabetes mellitus.
Pancreas: Diabetes mellitus, an endocrine disorder of carbohydrate metabolism resulting primarily from inadequate insulin release induces cognitive impairment and defects of LTP in the hippocampus, considered to be an important mechanism of learning and memory in mammals. As previously discussed, LTP is known to require regulation of the GluR properties. According to many studies, defects of long-term potentiation in the hippocampus of diabetic animals are due to abnormal GluRs 598 . For this reason it is possible that deficits in long-term potentiation during chronic diabetes might arise from dysfunction of the NMDA subtype of GluRs in early stages of the disease.
Investigation into the differential distribution of the GluR subunits in the pancreas showed that GluR 1 and GluR 4 were mainly localized to insulin-secreting cells in the central mass of the pancreatic islet, whereas GluR 2 / 3 was preferentially localized in the peripheral rim composed of non-insulin-secreting islet cells [84] [85] [86] 593, 599, 600 . It appears that insulin-and non-insulin-secreting cells express different AMPA receptor subunits, which may be used to mediate their hormone secretion 77, 78, 601 .
AMPA receptors are located in the α,β and pancreatic parenchyma [PP] cells, but are generally absent from the γ cells, whereas Ka receptors were expressed in the α and γ 602 . In addition to the GluRs, the presence of GABA receptors has also been reported in the PP cells 74, 134, 603 . Therefore, as with cells of the CNS, the balance in the activities of both GluR and GABA receptors probably determines the final effect on these cells.
Pituitary: Although GluRs have been described in the pituitary, the neurohypophysis possesses a two-fold higher binding activity than that found in the adenohypophysis 595 , the role of Glu, GluR and Glu transporters in pituitary disease is not clear, but they are important in modulation of the HPA 604 . mGluR 2/3 have a central role in modeling the anterior pituitary via induction of apoptosis 605 . mGluR 2/3 is not the only receptor to be described in the hypophysis. In addition to mGluR 2/3 , antibodies that are specific to GluR 1 and GluR 4 can be visualized in each lobe of the pituitary gland. Here, GluR 1 -and GluR 2/3 -positive cells can be identified in the anterior and intermediate lobe, and intense terminals of GluR 4 and weak terminals of GluR 2/3 were observed in the posterior lobe. The immunoreactivity appears to be at the axonal terminal of the neurosecretory magnocellular cells, suggesting that Glu might have an important role in regulation of the anterior pituitary 73 . More recently, GluR 6/7 subunits of Ka receptor showed up regulation in response to the systemic administration of a Glu agonis 606 , but MSG does not elicit a similar response 607 . How these receptors are expressed in such diseases as Cushing's syndrome and have yet to be investigated.
Some work has centered on release of various hormones and growth factors from the pituitary. Glu agonists, including AMPA, Ka, NMDA, and Glu elicit a luteinizing hormone releasing hormone [LHRH] release in vitro and the response is greatest for AMPA, which suggests that non-NMDA receptors are primarily involved in Gluinduced LHRH release 106, 608 . Indeed, mGluR activation stimulated the release of vasopressin [VP] and oxytocin [OT] 609 ; however, the relationship of GluRs to reproductive health still needs to be elucidated fully. Detailed characterization of the effects of agonists and antagonists of GluRs on growth hormone [GH] release revealed that activation of NMDA, Ka and AMPA receptors at different age-points resulted in clear-cut stimulation of GH secretion, although age-and sex-dependent differences were detected in the pattern of response to the different agonists 610 . This stimulatory action was proven NO-dependent and not exerted at the pituitary level. In addition, evaluation of the role of hypothalamic growth hormone-releasing hormone [GHRH] in the stimulatory action of NMDA by means of immunoneutralization of endogenous GHRH or destruction of GHRH producing neurons suggested the involvement of signals other than GHRH in this response. Similarly, it has been shown that immortalized gonadotrophin releasing hormone [GnRH] neurons (GT 1 cells) express GluRs when grown in culture and show enhanced GnRH secretion in response to GluR agonists 611, 612 . Interpretation of these findings with respect to disease of growth and reproduction can only be made when further research results have been published.
Adrenals: There is a dearth of literature regarding the role of GluRs in diseases affecting the adrenal medulla and cortex. GluR 1 is found in the zona glomerulosa [ZG] of the cortex, GluR 3 in the remaining parts of the cortex, GluR 2 in adrenal medullary cells and GluR 4 at a very low level in the ZG. All four GluR mRNAs are found in medullary ganglion cells where the flip form of GluR 2 and GluR 3 dominate and the GluR 2 mRNA is present in the arginine encoding form 613 . Different cell populations of the adrenal gland may express homomeric forms of different receptor subtypes 614 . Pineal: Glu inhibits NE-dependent melatonin synthesis 615 . Consistent with this observation, specific a g o n i s t s o f m G l u R 2 / 3 , i n c l u d i n g 1 -( 1 S , 3 R ) -aminocyclopentane-1,3-dicarboxylic acid [tACPD], inhibit NE-dependent melatonin synthesis, whereas agonists for other types of GluRs do not 615 . iGluRs have been shown to trigger microvesicle-mediated exocytosis of Glu from pineal cells 616 , which might serve as a feedback circuit for the above. The significance of these findings with respect to pineal function is not clear; however, one could postulate that Glu might be involved in effecting "jet lag".
Immune system
Several mGluRs, mGluR 1-3,5 , have been reported in the thymic stromal cell line [TC1S] and in thymocytes. TC1S expresses mGluR 2/3&5 , whereas thymocytes express mGluR 1,3&5 . The amount of each mGluR in unsorted thymocytes varies in relationship to one another: 70% expressed mGluR 5 , 50% mGluR 3 , and 15% mGluR 1 . In contrast, isolated CD 4 /CD 8 cells (double negative thymocyte precursor) 45% expressed mGluR 3 40%, and mGluR 1 whereas mGLuR 5 was barely detectable. Therefore, it has been hypothesized that changes in mGluRs subtype expressions may be related to T-cell maturation stages 617, 618 . Human T-cells have been shown to express functional iGluR 3 , indicating that both iGluR and mGluR are involved in lymphocyte activation and possible control 619 . GluRs are also expressed in other lymphoid tissues and inflammatory infiltrates 12, 102 , and experimental evidence indicates that human lymphocytes express iGluRs functionally operating as modulators of cell activation 620 . Glu is involved in signaling in immunocompetent cells and that the expression of both iGluRs and mGluRs may have regulatory functions in immunocompetent cells, as well as in the nervous system. More recently it has been found that Glu release by dendritic cells modulates T-cell activation 621, 622 , indicating that the CNS and immune system are truly connected. In fact, it has been suggested that autoimmunity to GluR is central to altered cell modulation 623 . NMDA-activated iGluR and mGluR 1,4-8 are expressed in lymphocytes, and do induce functional changes. Levels of exogenous and endogenous circulatory agonists and antagonists for lymphocyte GluRs, notably HC metabolites, are markedly increased in certain disease states and may be involved in disorders of the immune system 624 . The global picture of how Glu interacts with the immune system is still incomplete. As there is are a plethora of chemical and electrical interactions in the cell and in humoral mediated immunity, untangling the maze of interactions will be difficult. Nonetheless, the benefits of further research in this area could benefit those in autoimmune or immune compromised states.
Reproductive organs
Differential distribution of GluRs has been shown in reproductive organs of the male and female rat 102 . In the testis, these receptors have a specific affinity for different structures. There is intense anti-mGluR 2/3 immunolabeling of the head of the mature spermatids, spermatozoa, interstitial cells, myoid cells 102 , seminal vesicles 37 , and vas deferens 625 . This distribution suggests that GluRs may be involved in spermatogenesis, spermatozoa motility, testicular development, and vas deferens control. In fact, GluRs might be important for the contractile activity of the vas deferens and hence in the control of seminal fluid 625 . In the rat female reproductive system, GluRs also have a unique distribution within areas of the reproductive tract 102 . Antibodies have differential affinity to specific structures in the ovaries, the fallopian tubes, the cervix, the myometrium and the endometrium. In the ovary the distribution of GluRs within the follicles varies at different stages of their maturation 102 , an observation suggesting that these receptors may be involved in ovulation, fertilization, implantation of the ovum, and excitability of the uterus. The presence of the GluRs within the reproductive organs and the known functional effects of GABA and GABA receptors 626 suggest that similar excitatory-inhibitory neurotransmission interplay may also be present in the reproductive organs using GluRs as mediators.
It is possible that GluRs mediate some reproductive functions balanced with GABA receptor stimulation, such as gonadal maturation; steroidal sex hormone regulation; maturation, motility, and excitability of the spermatozoa 627 ; ovulation; fertilization; excitability of the fallopian tubes; implantation of the ovum; and excitability of the myometrium-may be all affected.
Three key GluR subunits (NMDAR 1 , AMPA-GluR 1 and Ka-GluR 6 ) fluctuate significantly during proestrus in the rat 628 . However, treatment with the antiprogestin, RU486 induces a significant elevation of GluR 6 mRNA levels during proestrus, suggesting that endogenous progesterone may act to inhibit hypothalamic GluR 6 levels 629 and that there might be co localization of the AMPA and progesterone receptors 630 . Similarly, estrogens, specifically β17-estradiol, are neuroprotective in a variety of models including Glu toxicity. Rat cortical neurons express NMDA and AMPA receptors, and are sensitive to brief periods of exposure to anoxia-reoxygenation or Glu. P r e t r e a t m e n t w i t h e s t r o g e n s a t t e n u a t e s G l u excitotoxicity and this protection is independent of the ability of the steroid to bind the estrogen receptor 631 . Supporting this finding, testosterone and estradiol show a stimulatory influence on the expression of AMPA receptors in the hypothalamus, but there are site and gender d i f f e r e n c e s . I n c r e a s e i n h y p o t h a l a m i c G l u R 2 / 3 concentrations by estradiol stimulation have been reported as two times higher in females, compared with males, whereas the changes in hypothalamic GluR 1 levels showed no sex differences 612 . Some research has been done on the developing fetus and Glu metabolism. The transport and metabolism of glutamine and Glu exhibits unique characteristics that clearly emphasize the importance of the interaction between the placenta and the fetal liver 632 . Glutamine is delivered into the fetal circulation at a rate that is the highest of all the amino acids; however, the placenta extracts 90% of fetal plasma Glu.
Conversely, the fetal liver has a large net output of Glu but also uptakes glutamine. As development progresses changes can be noted in both glutamine and Glu. At parturition, a striking reduction in Glu output from the fetal liver occurs, leading to a fall in fetal arterial Glu concentrations and a marked decrease in placental Glu uptake. This observation is correlated with a marked decrease in progesterone output from the pregnant uterus 632 .
Cardiovascular
In monkey and rat hearts, various GluRs have been found in cardiac intramural nerve fibers and ganglia cells in the conducting system 633, 634 , and similar findings have been seen in human hearts 90 . In these studies, antibodies to GluR 2,3 , GluR 5-7 , Ka 2 , and NMDAR 1 showed the strongest signals and were specifically localized to cardiac nerve terminals, ganglia, conducting fibers, and some to myocardiocytes particularly in the atrium. Each antibody portrayed a specific pattern of distribution 98 . These structures are central to cardiac excitation and rhythmic control 6 35 -6 37 . The presence on GluRs in myocardium, conducting system, nerve fibers and intramural ganglia cells in all three species, strongly supports the view that these receptors may play a role in the physiology and pathophysiology of cardiac rhythm and excitation 90, 638 . L-Glu increases the frequency of Ca ++ oscillations 639 , which have been positively correlated with increased contraction frequency in myocardial cells. Such an increase could reduce cardiac filling, hypoxia and angina-like chest pains. In fact, non-NMDA, but not NMDA and mGluRs in the commissural nucleus of the solitary tract play an important role in the sympathoexcitatory reflex response to activation of cardiac receptors during myocardial ischemia 640 . It is likely that the concentration of Glu and the number of GluR will modulate this effect 641 . Experimental evaluation of the effect of Glu on blood pressure in anesthetized rats showed that following intrathecal injection of mGluR agonists at the thoracolumbar level of the spinal cord, activated Group I, II and III mGluRs (mGluR 1-8 ), and increased the mean blood pressure. In contrast, low doses of Group II mGluR (mGluR 2/3 ) agonists induce hypotension and bradycardia following blockade of NMDA receptors 642 . It is possible that modulation of Glu and GluR could be used in the future for ameliorating hypoxic cardiovascular disease and hypertension. In the real life situation, cardiac lesions have been seen in sea lions that died of DMA toxicity along the coast of California 189, 644, 645 implying that EAAs and Glu play and important role in cardiac pathology.
Lungs
Adult respiratory distress syndrome [ARDS], where excessive activation of the NMDAR 1 in the lungs induces acute edema and lung injury 105, 646 , is often a fatal disorder. The injury in ARDS can further be modulated by blockage of one of three critical steps: NMDA 1 binding, inhibition of NO s y n t h e s i s , o r a c t i v a t i o n o f p o l y ( A D P -r i b o s e ) polymerase 105, 646 . Immunolabeling for various GluRs in bronchial epithelium, blood vessels of the lungs, mast cells, and inflammatory cells has been reported 90 , which supports the view that GluRs play a role in airway responses to injury and inflammation.
Their presence in the airway structures such as the larynx, esophagus and mast cells also implicate the GluRs in the mediation of asthmatic episodes 33, 105, 646 . The excitation of GluRs in the air passages therefore may be important in airway inflammation and hyper reactivity observed in bronchial asthma 647 . Their presence also could explain the enhancement of acute asthmatic attacks by Glu-containing foods 33 . Mast cells, central to histamine release and asthma, are found in the connective tissues throughout the body. Spermidine-induced release from the mast cells is dependent on the presence of Ca ++ in the external milieu 648 . The influx of Ca ++ following spermidine administration is accompanied by NMDAR 1 activation, and the increased intracellular Ca ++ concentration initiates the exocytotic degranulation process in mast cells and release of histamine.
Spermine is a natural polyamine, and binding sites for polyamines facilitates the opening of the ion channel associated with NMDA receptors. In neuronal tissue, polyamine triggers histamine secretion through interaction with a polyamine site associated with an NMDAR 1 macro complex. Therefore, spermine can modulate activation of the macro complex, either through action at polyaminebinding sites in the lung or at other sites. The antagonists of NMDAR 1 block this release of histamine secretion that was induced by the natural polyamine-spermine. When the NMDAR 1 is present it is possible that EAAs can also influence allergic reactions.
Kidneys and liver
The wide distribution of NMDAR 1 and the presence of mGluR 2/3 and AMPA-GluR 2,3 in the juxtaglomerular apparatus [JGA] and proximal tubules 102 , suggests that these receptors may be involved in electrolyte and water homeostasis, probably associated with the control of renin release . In contrast, D 1A is not present in JGA and the ascending loop of Henle, whereas D 1B is present in these regions. Experimental data suggests that DARs are involved in r e n a l h e mo dy nam ic s , io n t ra n s po rt a nd ren in secretion 92, 650, 651 . In addition to the GluRs and the DARs, GABA A and GABA B receptors have been localized to the renal cortex 134 . Therefore, GABA might also balance the effects of GluRs on renal functions within in the kidney cortex rather than the medulla.
H e p a t i c i G l u R s a n d m G l u R s h a v e b e e n demonstrated 98, 99 . In vitro, mGluR 5 in primary cultured hepatocytes stimulates the hydrolysis of inositol phospholipids 99 . The effects of mGluRs agonists were examined with anoxia-induced cell damage, where the agonists reduced the viability of hypoxic hepatocytes compared with controls. But not all agonists had this effect. It has been suggested that GluR is activated by the Glu present in the portal blood and may contribute to the liver damage under adverse conditions.
Gastrointestinal tract
GluRs have been reported in the stomach, duodenum and descending colon, of the gastrointestinal tract [ G I T ] 9 1 , 9 5 -9 7 , 6 5 2 w h e r e s t a i n i n g w a s s e e n i n t h e enteroendocrine cells, ganglia cells and nerve fibers have been seen throughout the GIT 653 . Glu induces contraction of the ileal longitudinal smooth muscle and myenteric plexus 96 , and mGluRs play a role in neurotransmission 83 and in the enteric reflexes, where Glu, GABA and NMDA receptors 95 are involved intestinal motility at the myenteric plexus, as vesicular Glu transporters [VGLUT] 600, 654 , in muscle 655 and in the stomach contractions 656 . These effects can be blocked noncompetitively by NMDA but not by Ka or quisqualate antagonists 657 . In the CNS, electrophysiological L-Glu and L-Asp are less potent than NMDA due to their avid uptake by the tissue 102 , but there appears to be an absence of the uptake processes of these compounds in the myenteric plexus 95, 96 . However, Glu and Asp are both involved in regulating acid secretion in the stomach, but the mode of action of each is different 652, 658 . Asp was more specific than Glu in regulating acid secretion. This was attributed to the fact that Glu is a general agonist for all types of GluRs, yet Asp is a potent agonist for NMDAR receptors. Interestingly, NMDA receptor influences opioid release from enteric neurons 659 . Glu, GluRs, and GluTs also act in a more central manner in the GIT tract via the vagus 660 , where afferent vagal transmission is done via the left vagal afferent fibers via nonNMDA receptors to neurons 661 . In addition, the effect on vagal activity impacts the hepatoportal and pancreatic systems through either up regulating or down regulating vagal activity. It has been suggested also that this effect may account for the GIT upsets experience by some individuals following ingestion of MSG 662 . The application of knowledge regarding the Glu system may lie in its potential prognostic value in some neoplasia, investigating Glu analogues, and irritable bowel syndrome [IBS] . Initial work along this track has shown that mGluR 4 signaling is seen in colorectal carcinomas, and that over expression of mGluR 4 is associated with a poor prognosis 124 . There is some question as to whether the dorsal horn neurons may be involved in intestinal motility, where antagonizing GluR corresponds to colonic distension 663 . The practical implication of this finding may lie in treatment of IBS.
Musculoskeletal
Although it has been recognized that muscle stores Glu, most work on GluRs has been done in invertebrates 664 . However, there are some reports of research done in mammals, particularly in the realm of muscular pain control 665 . In fact, most work on muscles has been on smooth muscle in other organs such as the gastrointestinal tract 666 , and of course, the nervous system effects on muscle 667 . Bone has been shown to contain different GluRs subunits: GluR 2,3 , NMDAR 1 , mGluR 2,4,5&7 668 , and bone cells have the potential to express many of the molecules associated with the Glu-mediated signaling 669, 670 . In fact, it has been suggested that GluRs in bone are a novel means of paracrine communication in the skeleton 671 , although there is still a question regarding the role of Glu in controlling bone growth 672 . Nonetheless, all osteoblasts 673, 674 . osteocytes, and osteoclasts express one or more of the GluRs subunits 111, 675 , and intrinsic control of Glu signaling occurs by releasing Glu 676 . Interestingly, NMDA type Glu receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors 677, 678 . The blockade of NMDA receptors with antagonists results in inhibition of osteoblast formation, suggesting that most abundant NMDAR 1 is functional in bone 679 and that it is involved in osteoclast differentiation 680 . So, although total control of bone growth is not under Glu control, it certainly seems as though Glu, GluRs, and GluTs affect individual cell types.
GLAST has also been identified in bone 111 , further supporting the view that EAAs may play a role in paracrine signaling in bone cells 681 . The GLAST performs an essential function during Glu-mediated synaptic neurotransmission by acting as a high affinity uptake system to remove released Glu from the synaptic cleft, thus preventing over stimulation of the postsynaptic Glu receptors 682 .
Skin
Most of the literature regarding the functional effects of GluR and skin relates to pain as an endpoint. However, GluRs have been reported in skin 112 and keratinocytes 101, 683 . So far mGluRs and iGluRs, including NMDA and AMPA, have been described 100 and there are suggestions that desensitization of GluRs may contribute to tolerance seen in s e n s o r m o t o r c o n n e c t i o n s f o l l o w i n g m u l t i p l e stimulations 684, 685 . It appears as though Group II mGluR 2/3 are involved in this process 686, 687 . Interestingly, mGluR 5 have been found on human melenocytes; however, their action is still uncertain, but has been hypothesized to be in the control of melenocyte proliferation 688 . Perhaps we will understand the role of mGluR 5 in melanomas in the future, so eventually GluR might be used in prognostication and treatment of these malignancies.
Taste: Taste receptor cells [TRCs] are specialized epithelial cells that are clustered together into ovoid end organs located in the epithelium of the tongue, the soft palate, and the epiglottis 681 . On the tongue, taste buds are found in fungiform, foliate, and vallate taste papillae. Both the detection of chemical stimuli and the synaptic activity rely on the presence of specific membrane proteins 689, 690 . Among these proteins, GluRs play a key role in TRCs' physiology 691 , acting as molecular sensors for food L-Glu and as synaptic receptors in glutamatergic interactions with nerve endings 692 . Indeed, messenger RNAs encoding several ionotropic subunits and an mGluR 4 -like receptor have been identified in taste papillae 693, 694 , and are probably stimulated by MSG 88 . Of the Glu and GluR, the NMDA receptor serves as a primary taste transducer for MSG, and an mGluR modulates the flavor enhancing effect of MSG 695 .
Summary and Conclusions
Glutamate is the most common neurotransmitters, as Lglutamic acid is present in most foods, found in either the free form or bound to peptides and proteins. In fact, the Glu system is ubiquitous across most animal taxa and has been found in plants. The most abundant molecular component of the Glu system is NAAG.
Glutamate receptors perform a variety of functions in the central and peripheral nervous systems such as learning, memory, anxiety, and the perception of pain. They consist of two subtypes: ionotropic and metabotropic glutamate receptors. iGluRs are a group of transmembrane ion channels that open in response to NMDA, Ka and AMPA. mGluRs are active through an indirect metabotropic process. They are members of the Group C family of G-proteincoupled receptors the activation of which has been established to be neuroprotective in vitro and in vivo. Unlike iGluRs, mGluRs are not directly linked to ion channels, but may affect them by activating biochemical cascades.
Endogenous Glu, by activating NMDA, AMPA or mGluR 1 receptors, may contribute to the brain damage occurring acutely after status epilepticus, cerebral ischemia or traumatic brain injury. Endogenous Glu may also contribute to chronic neurodegeneration in such disorders as ALS, AD, PD, MS, and HD. Other clinical conditions that may respond to drugs acting on glutamatergic transmission include epilepsy, amnesia, anxiety, hyperalgesia and psychosis.
Although the CNS, PNS and ANS are the regions where most work has been done identifying the GluRs and their agonistic and antagonistic effects, a reasonable amount of data is available for review for other tissues. Regardless of the current information available, there are many missing pieces in the Glu, GluR and GluT picture, which hopefully will be clarified in the not too distant future. These missing pieces will be necessary to fully describe the function and structure of the Glu system. It is quite probable that in years to come we will understand that the Glu system plays a more central role in many more disease entities than have been investigated thus far. Calabresi P, and Pisani A. Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 f u n c t i o n i n s t r i a t a l c h o l i n e r g i c i n t e r n e u r o n s . 
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